Analyst Reco. Evolent Health, Inc.

Equities

EVH

US30050B1017

Real-time Estimate Cboe BZX Other stock markets 01:00:24 2024-04-23 pm EDT			5-day change	1st Jan Change
30.42 ^USD	+1.86%		+1.03%	-7.75%

Apr. 22	Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target	MT
Mar. 28	Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Starts Coverage on Evolent Health With Buy Rating, $40 Price Target	Apr. 22	MT
Canaccord Genuity Trims Price Target on Evolent Health to $44 From $45, Maintains Buy Rating	Mar. 28	MT
JPMorgan Trims Price Target on Evolent Health to $52 From $53, Maintains Overweight Rating	Mar. 15	MT
Canaccord Genuity Cuts Price Target on Evolent Health to $45 From $47, Maintains Buy Rating	Feb. 23	MT
JMP Securities Initiates Evolent Health With Market Outperform Rating, Price Target is $37	Dec. 06	MT
RBC Trims Price Target on Evolent Health to $42 From $44, Keeps Outperform Rating	Nov. 28	MT
Truist Securities Trims Price Target on Evolent Health to $34 From $36, Maintains Hold Rating	Nov. 14	MT
UBS Starts Evolent Health With Buy Rating, Price Target is $46	23-10-16	MT
Guggenheim Adjusts Price Target on Evolent Health to $47 From $50, Maintains Buy Rating	23-06-26	MT
Stephens Initiates Evolent Health at Overweight With $40 Price Target	23-04-12	MT
Cowen Adjusts Price Target on Evolent Health to $59 From $57, Maintains Outperform Rating	23-01-30	MT
Cowen Adjusts Evolent Health's Price Target to $57 From $52, Keeps Outperform Rating	22-11-18	MT
Truist Securities Starts Evolent Health at Hold With $33 Price Target	22-11-01	MT
Canaccord Genuity Cuts Evolent Health's Price Target to $48 From $55, Reiterates Buy Rating	22-10-12	MT
BTIG Trims Evolent Health's Price Target to $45 From $55, Keeps Buy Rating	22-10-12	MT
JPMorgan Adjusts Evolent Health's Price Target to $52 From $37, Reiterates Overweight Rating	22-08-19	MT
RBC Raises Price Target on Evolent Health to $44 From $40, Maintains Outperform Rating	22-08-03	MT
BTIG Adjusts Evolent Health's Price Target to $50 From $45, Reiterates Buy Rating	22-08-03	MT
Piper Sandler Adjusts Evolent Health's Price Target to $40 From $35, Reiterates Overweight Rating	22-08-03	MT
RBC Initiates Evolent Health at Outperform With $40 Price Target, Sees 'Significant Organic Revenue Growth Opportunity'	22-07-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Evolent Health, Inc.

Equities

EVH

US30050B1017

Analyst Reco.

Filters